Dose escalation study of targeted alpha therapy with [225Ac]Ac-DOTA-substance P in recurrence glioblastoma - safety and efficacy.

Leszek KrólickiFrank BruchertseiferJolanta KunikowskaHenryk KoziaraDariusz PawlakRadosław KulińskiRafał RolaAdrian MerloAlfred Morgenstern

Published in: European journal of nuclear medicine and molecular imaging (2021)

Treatment of recurrent glioblastoma with [225Ac]Ac-DOTA-SP is safe and well tolerated up to 30 MBq per cycle. The escalation dose protocol showed good tolerability. Only mild temporary adverse effects were observed. No remarkable haematological, kidney and liver toxicity was seen.

Keyphrases

open label
pet ct
pet imaging
randomized controlled trial
oxidative stress
clinical trial
stem cells
smoking cessation
cell therapy